Application No.: 10/028,172 Docket No.: 322732000401

AMENDMENTS TO THE CLAIMS

Claims 1-30 (Cancelled)

- Claim 31 (New): A diagnostic reagent for hepatitis C virus (HCV) infection comprising a solid phase sensitized with a genetic recombinant HCV antigen and synthesized HCV antigens which comprise core peptide, NS4 peptide and NS5 peptide.
- Claim 32 (New) The diagnostic reagent of claim 31, wherein the genetic recombinant HCV antigen is an HCV non-structural region proteins.
- Claim 33 (New): The diagnostic reagent of claim 31, wherein the genetic recombinant HCV antigen is NS3 antigen.
- Claim 34 (New): The diagnostic reagent of claim 31, wherein the synthesized HCV antigen is selected from the group consisting of HCV non-structural region proteins and HCV structural region proteins.
- Claim 35 (New): The diagnostic reagent of claim 31, wherein the solid phase is directly sensitized with the genetic recombinant HCV antigen.
- Claim 36 (New): A diagnostic reagent for hepatitis C virus (HCV) infection comprising a solid phase sensitized with a genetic recombinant HCV antigen and one or more synthesized HCV antigens, wherein the synthesized HCV antigen is conjugated with a carrier protein.
- Claim 37 (New): The diagnostic reagent of claim 36, wherein the synthesized HCV antigen is selected from the group consisting of core peptide, NS4 peptide and NS5 peptide.
- Claim 38 (New): The diagnostic reagent of claim 36, wherein the synthesized HCV antigen is selected from the group consisting of HCV non-structural region proteins and HCV structural region proteins.

sd-171655 2

Application No.: 10/028,172 Docket No.: 322732000401

Claim 39 (New): The diagnostic reagent of claim 36, wherein the synthesized HCV antigen comprises core peptide, NS4 peptide and NS5 peptide.

Claim 40 (New): The diagnostic reagent of claim 36, wherein the carrier protein and the synthesized HCV antigen are present at a ratio of about 1:3 to 1:20 (carrier protein: synthesized HCV antigen).

- Claim 41 (New): The diagnostic reagent of claim 36, wherein the carrier protein is a water-soluble protein.
- Claim 42 (New): The diagnostic reagent of claim 41, wherein the water-soluble protein is selected from the group consisting of BSA, ovalbumin and hemocyanin.
- Claim 43 (New): The diagnostic reagent of claim 36, wherein the genetic recombinant HCV antigen is conjugated with a carrier protein.
- Claim 44 (New): A diagnostic reagent for hepatitis C virus (HCV) infection comprising a solid phase sensitized with a genetic recombinant HCV antigen and one or more synthesized HCV antigens, wherein the genetic recombinant HCV antigen is conjugated with a carrier protein.
- Claim 45 (New): The diagnostic reagent of claim 44, wherein the genetic recombinant HCV antigen is selected from HCV non-structural region proteins.
- Claim 46 (New): The diagnostic reagent of claim 44, wherein the genetic recombinant HCV antigen is NS3 antigen.
- Claim 47 (New): The diagnostic reagent of claim 44, wherein the synthesized HCV antigen is selected from the group consisting of core peptide, NS4 peptide and NS5 peptide.

3

sd-171655

Application No.: 10/028,172 Docket No.: 322732000401

Claim 48 (New): The diagnostic reagent of claim 44, wherein the synthesized HCV antigen is selected from the group consisting of HCV non-structural region proteins and HCV structural region proteins.

Claim 49 (New): The diagnostic reagent of claim 44, wherein the carrier protein is a water-soluble protein.

Claim 50 (New): The diagnostic reagent of claim 49, wherein the water-soluble protein is selected from the group consisting of BSA, ovalbumin and hemocyanin.

Claim 51 (New): A diagnostic reagent for hepatitis C virus (HCV) infection comprising a solid phase sensitized with a genetic recombinant HCV antigen and one or more synthesized HCV antigens, wherein the solid phase is carrier particles.

Claim 52 (New): The diagnostic reagent of claim 51, wherein the synthesized HCV antigen is selected from the group consisting of core peptide, NS4 peptide and NS5 peptide.

Claim 53 (New): The diagnostic reagent of claim 51, wherein the synthesized HCV antigen is selected from the group consisting of HCV non-structural region proteins and HCV structural region proteins.

Claim 54 (New): The diagnostic reagent of claim 51, wherein the synthesized HCV antigen comprises core peptide, NS4 peptide and NS5 peptide.

Claim 55 (New): The diagnostic reagent of claim 51, wherein the carrier particle is selected from the group consisting of polystyrene latex particle, copolymer latex particle, erythrocyte and gelatin particle.

4

sd-171655